Paul Zimmermann, MD
Clinical Cardiac Electrophysiology · Camden, SCNPI 1629002332
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $783 and has fallen 82.1% since, to $140 in 2023. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in SC, where the typical reported total is $35,448.
Across 115 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$289
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$271
- Amgen$246
- Johnson & Johnson$211
- E.r. Squibb & Sons, L.L.C.$187
- Pfizer$122
- plus $639 from 14 others
What the payments were for
- Food & beverage$1,95399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $289 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $271 |
| Amgen | 12 | $246 |
| Johnson & Johnson | 15 | $211 |
| E.r. Squibb & Sons, L.L.C. | 13 | $187 |
| Pfizer | 8 | $122 |
| Amarin Pharma, Inc. | 6 | $110 |
| Sanofi-aventis U.S. LLC | 5 | $99 |
| Abbott | 4 | $90 |
| AstraZeneca | 4 | $58 |
| Boehringer Ingelheim | 3 | $57 |
| Biotronik Inc. | 3 | $55 |
| Merck | 2 | $33 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Cvrx, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
How this compares
$1,965 in reported general payments places this provider in the 10th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
See all clinical cardiac electrophysiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 493 | $423,848 |
| EntrestoSacubitril/Valsartan | 184 | $166,154 |
| XareltoRivaroxaban | 144 | $125,097 |
| Repatha SureclickEvolocumab | 99 | $102,187 |
| MultaqDronedarone Hcl | 42 | $34,804 |
| JardianceEmpagliflozin | 21 | $21,836 |
| FarxigaDapagliflozin Propanediol | 26 | $18,268 |
| Praluent PenAlirocumab | 18 | $17,362 |
| BrilintaTicagrelor | 31 | $15,450 |
| CorlanorIvabradine Hcl | 12 | $7,537 |
| Metoprolol Succinate | 460 | $5,844 |
| Valsartan | 260 | $5,694 |
| Rosuvastatin Calcium | 321 | $4,019 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 28 | $3,720 |
| Ranolazine ErRanolazine | 27 | $3,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $423,848493 claims |
| NovartisEntresto | $289 | $166,154184 claims |
| Johnson & JohnsonXarelto | $211 | $125,097144 claims |
| Sanofi-aventis U.S. LLCMultaq | $99 | $34,80442 claims |
| AstraZenecaFarxiga, Brilinta | $58 | $33,71857 claims |
| Boehringer IngelheimJardiance | $57 | $21,83621 claims |
| AmgenCorlanor | $246 | $7,53712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
Other clinical cardiac electrophysiology in Camden
- Jeffrey WinterfieldCharleston$498K
- Frank CuocoCharleston$306K
- Anne KromanCharleston$279K
- Andrew BrenyoRock Hill$241K
- Joseph ManfrediGreenville$213K
- Michael GoldCharleston$204K
- Sultan SiddiqueColumbia$182K
- Peter NetzlerGreenville$146K
- Yuxuan MaoLittle River$126K
- Chad WardClemson$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.